Serinus BiosciencesCombinations therapy by rational design

Serinus Biosciences: Pioneering Solutions for Cancer Drug Resistance

Introduction

Serinus Biosciences is at the forefront of developing innovative treatments to combat cancer drug resistance. Our mission is to design drugs that target the unique vulnerabilities of drug-resistant tumors, providing new hope for patients who have exhausted other therapeutic options.

Key Features

• ResCuETM AI Platform: The first AI-driven platform to identify druggable vulnerabilities induced by tumor resistance mechanisms.
• Proteomic Mapping: Harmonizes cancer-specific proteomic maps and drug response readouts.
• Synthetic Lethality: Utilizes the principles of synthetic lethality to target drug-resistant tumors.
• Precision Medicine: Designs next-generation precision medicine drugs for treatment-resistant patients.

Use Cases

• Target Discovery: Identifying new drug targets to overcome resistance to existing clinical compounds.
• Combination Therapy: Prioritizing combinations for developmental compounds to enhance treatment efficacy.
• Collaborative Research: Partnering with leading pharma and biotech companies to co-develop innovative solutions.

Pricing

Our pricing model is tailored to the specific needs of our partners and collaborators. We offer flexible co-development partnerships and target discovery services to ensure the best outcomes for our clients.

Teams

Our team comprises leading scientists, researchers, and industry experts dedicated to overcoming the challenges of cancer drug resistance. We work collaboratively with pharma and biotech companies to bring groundbreaking treatments to market.

Join us in our mission to battle cancer drug resistance and provide new treatment opportunities for patients worldwide. Get in touch with us to learn more about our innovative solutions and partnership opportunities.